Jacobs & Co. CA Grows Position in Sanofi SA (NYSE:SNY)

Jacobs & Co. CA raised its holdings in shares of Sanofi SA (NYSE:SNY) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,855 shares of the company’s stock after buying an additional 400 shares during the quarter. Jacobs & Co. CA’s holdings in Sanofi were worth $549,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. First Trust Advisors LP grew its holdings in shares of Sanofi by 14.3% during the third quarter. First Trust Advisors LP now owns 893,108 shares of the company’s stock worth $41,378,000 after buying an additional 111,701 shares in the last quarter. Managed Asset Portfolios LLC grew its holdings in shares of Sanofi by 14.9% during the third quarter. Managed Asset Portfolios LLC now owns 612,855 shares of the company’s stock worth $28,394,000 after buying an additional 79,686 shares in the last quarter. Keeler Thomas Management LLC boosted its position in shares of Sanofi by 17.3% during the 3rd quarter. Keeler Thomas Management LLC now owns 29,800 shares of the company’s stock valued at $1,380,000 after acquiring an additional 4,400 shares during the last quarter. Bartlett & Co. LLC acquired a new position in shares of Sanofi during the 3rd quarter valued at about $84,000. Finally, Parallel Advisors LLC boosted its position in shares of Sanofi by 50.3% during the 3rd quarter. Parallel Advisors LLC now owns 6,681 shares of the company’s stock valued at $310,000 after acquiring an additional 2,235 shares during the last quarter. 7.04% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Sanofi sold 172,904 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.

Shares of SNY stock traded up $0.38 on Friday, hitting $45.86. 1,911,995 shares of the stock traded hands, compared to its average volume of 1,307,250. The firm’s 50-day moving average price is $45.85 and its two-hundred day moving average price is $43.37. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock has a market capitalization of $114.86 billion, a PE ratio of 14.65, a PEG ratio of 2.41 and a beta of 0.67. Sanofi SA has a twelve month low of $40.00 and a twelve month high of $47.47.

SNY has been the topic of several recent research reports. Sanford C. Bernstein initiated coverage on shares of Sanofi in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price target on the stock. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Thursday, August 29th. UBS Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Guggenheim raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, October 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $49.50.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Stop Order

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit